Share This Page
Suppliers and packagers for LUTATHERA
✉ Email this page to a colleague
LUTATHERA
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Aaa Usa Inc | LUTATHERA | lutetium lu 177 dotatate | SOLUTION;INTRAVENOUS | 208700 | NDA | Advanced Accelerator Applications USA, Inc | 69488-003-01 | 1 VIAL in 1 PACKAGE (69488-003-01) / 20.5 mL in 1 VIAL | 2018-01-26 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
ppliers for the Pharmaceutical Drug: LUTATHERA
Introduction
LUTATHERA (lutetium Lu 177 dotatate) represents a significant advancement in targeted peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs). Developed to deliver targeted radiation, LUTATHERA has gained regulatory approval worldwide, leading to a complex global supply chain involving multiple stakeholders. Ensuring reliable sourcing of LUTATHERA is vital for healthcare providers and pharmaceutical distributors aiming to meet patient demand and maintain therapeutic efficacy.
Manufacturers of Lutetium-177 for LUTATHERA
Lutetium-177 Production
The core component of LUTATHERA—lutetium-177 (^177Lu)—is a radionuclide produced primarily through two methods: neutron irradiation of ytterbium-176 (^176Yb) in nuclear reactors and via accelerator-based routes. The choice of production method impacts availability, purity, and supply stability.
Key Suppliers
- PerkinElmer and ITG (Igen Int.)
As early players, these companies produce high-purity ^177Lu using reactor-based methods, primarily for clinical and research purposes. They have established quality assurance protocols aligning with regulatory standards such as European Pharmacopoeia and USP. - NTP Radioisotopes (South Africa)
A leading global supplier, NTP produces ^177Lu through neutron irradiation in the SAFARI-1 research reactor, offering large batch sizes suitable for commercial-scale pharmaceutical manufacturing. Their products are utilized in numerous clinical applications worldwide, including LUTATHERA. - ILL (Institut Laue-Langevin, France) and Osiris reactor (France)
Historically involved in research and limited production, these facilities contribute to the supply chain primarily through research-grade ^177Lu, although scaled commercial production remains limited.
Future and Emerging Suppliers
- Advanced Accelerator Applications (AAA/Eli Lilly)
As the developer and manufacturer of LUTATHERA, AAA (a subsidiary of Eli Lilly) sources ^177Lu from multiple global suppliers, including NTP, to ensure sufficient supply volumes. Eli Lilly has invested in expanding production capacity and securing long-term supply contracts with leading isotope producers. - ITM Isotopen Technologien München AG (Germany)
A notable emerging player, ITM plans to establish a dedicated ^177Lu production facility leveraging accelerated particle irradiation, aiming to meet rising global demand and reduce dependence on reactor-based supply.
Raw Material Suppliers and Target Material Providers
The production of ^177Lu depends on the availability of highly enriched ytterbium-176 (^176Yb) targets. Major suppliers include:
- Oak Ridge National Laboratory (ORNL), USA
Supplies enriched ^176Yb for isotope production, especially under cooperative federal programs. - Ceradyne/Eli Lilly
Engaged in sourcing or producing enriched Yb-176 for internal use and partner production. - Commercial suppliers such as Axcelis Technologies and Siemens provide target fabrication and irradiation services.
Manufacturing Pipelines and Contract Manufacturers
Multiple Contract Manufacturing Organizations (CMOs) engage in the production of LUTATHERA to meet global demand. They focus on:
- Radiolabeling Processes
Conjugation of ^177Lu to somatostatin analogs (e.g., DOTATATE) in GMP-compliant facilities. - Quality Control and Distribution
Ensuring radiochemical purity, sterility, and proper labeling prior to distribution to hospitals and clinics.
Major CMOs such as AZORpharma and Nordion have capacity and regulatory approvals to produce LUTATHERA, often collaborating directly with Eli Lilly or authorized distributors.
Supply Chain Challenges and Market Dynamics
Supply Security
Limited reactor-based ^177Lu production capacity creates bottlenecks, especially with the upcoming retirements of aging reactors. Adequate supply hinges on expanding production capabilities, such as new accelerator-based methods and dedicated isotope reactors.
Regulatory and Quality Standards
Suppliers must meet rigorous standards, including FDA, EMA, and ICH guidelines, which influence procurement timelines and logistics.
Geopolitical Considerations
The production and supply chains are influenced by geopolitical factors, including regulatory changes, export controls, and nuclear safety regulations, which impact source reliability.
Strategic Implications for Stakeholders
Healthcare providers and distributors should establish long-term procurement agreements with diversified suppliers to mitigate shortages. Pharmaceutical companies should monitor isotope production facility expansions and technological innovations, such as accelerator-based isotope production, for potential supply diversification.
Investors and decision-makers must remain vigilant regarding regulatory approvals, capacity expansions, and geopolitical developments affecting supply continuity.
Key Takeaways
- The main ^177Lu supply for LUTATHERA originates from nuclear reactor-based producers such as NTP Radioisotopes and research institutions like ORNL.
- Eli Lilly, through AAA, sources ^177Lu from multiple suppliers, including NTP, to assure stable LUTATHERA manufacturing.
- Emerging technologies like accelerator-based production are poised to enhance supply security and reduce reliance on aging nuclear reactors.
- The complex supply chain involves raw material providers, isotope producers, contract manufacturers, and distributors—each critical to maintaining supply integrity.
- Stakeholders should prioritize diversification, capacity expansion, and regulatory compliance to mitigate supply risks.
FAQs
1. Who are the primary producers of lutetium-177 used in LUTATHERA?
Major producers include NTP Radioisotopes (South Africa), PerkinElmer (USA), and historically, research institutions like ORNL. Eli Lilly’s subsidiary, AAA, sources isotope from these providers to manufacture LUTATHERA.
2. Are there any emerging suppliers to watch for in the LUTATHERA supply chain?
Yes. Companies like ITM Isotopen Technologien München are developing accelerator-based ^177Lu production, promising increased capacity and supply security.
3. What are the main challenges in ensuring a stable supply of LUTATHERA?
Limited reactor-based production capacity, aging infrastructure, geopolitical factors, and regulatory hurdles pose supply stability risks. Expansion of accelerator-based methods aims to mitigate these issues.
4. How does the supply chain impact the pricing and availability of LUTATHERA?
Supply constraints, production costs, and technological investments influence pricing. Supply disruptions can lead to shortages, affecting patient access and therapeutic planning.
5. What role do regulatory agencies play in LUTATHERA’s supply?
Regulatory agencies ensure quality and safety standards are met, which influence manufacturing approvals, licensing, and distribution. They also facilitate international cooperation to ensure consistent supply.
References
- European Medicines Agency. LUTATHERA (lutetium Lu 177 dotatate).
- IAEA. Production and Quality Control of Lutetium-177.
- Eli Lilly and Company. LUTATHERA Manufacturing and Supply Updates.
- NTP Radioisotopes. Product specifications and capacity reports.
- ITM Isotopen Technologien München AG. Development of Accelerator-based Lutetium-177.
More… ↓
